BANGALORE, India I January 18, 2014 I Biocon Ltd, Asia's premier biotechnology company, today introduced CANMAb (150 mg/ 440 mg), a Trastuzumab for Injection 440mg is also known as Canmab and Manufactured by Biocon Ltd., India.. These threats will hit the firm far harder than any lost sales in India. Roche sues Biocon and Mylan over biosimilar version of Herceptin;Delhi HC grants injunction. The drug will be available at about 25% discount to the current list price of the reference product in India. Roche challenges Biocon, Mylan, DCGI over launch of biosimilar version of its breast cancer drug Herceptin This website is designed and maintained for all cancer patients and their families in India only. CANMAb , developed jointly by Biocon and Mylan under a global partnership, trastuzumab is being introduced for the benefit of patients in India. It is available in strength of 440mg. Trastuzumab is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor [] Biocon . Prices. CANMAb, developed jointly by Biocon and Mylan under a global partnership, is the worlds first biosimilar version of Herceptin and is being introduced for the benefit of patients in India. Biocon Introduces CANMAbTM - Worlds First Biosimilar Trastuzumab for Treating Breast Cancer in India ADITYA PHARMA - Exporter, Manufacturer & Supplier of Canmab 440mg ( Trastuzumab ) Injection based in Delhi, India Herceptin generated global sales of $6.4 billion in 2012 and $21 million in India. CANMAb Blogs, Comments and Archive News on Economictimes.com Biocon offers affordable & convenient CANMAb to treat HER2-positive breast cancer in India ... which is already significantly lower than its price in developed markets. CANMAb Latest Breaking News, Pictures, Videos, and Special Reports from The Economic Times. ... director at Biocon. CANMAb will offer a high quality, more affordable option to breast cancer patients in India. What is Canmab (Trastuzumab)? Trastuzumab is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor [] Biotechnology major Biocon will start selling breast cancer drug 'CANMAb', developed jointly with US-based Mylan, in the country from next month. Also view other alternatives Canmab is the generic version of Roches patented drug Herceptin or Herclon. Price wars. Its generic name is Trastuzumab. Also view other alternatives Biocon will sell its version of Herceptin, which it is calling Canmab, in two different dosage sizes. CANMAb will offer a high quality, more affordable option to breast cancer patients in India. 440mg (1 Vial) MRP Our Price; Rs. MUMBAI: Bangalore-based drugmaker Biocon on Saturday launched CANMAb, the biosimilar version of anti-cancer drug Herceptin, a move that analysts say would be a 29 November 1978Biocon India is incorporated as a joint venture between ... Biologic Treatment for Psoriasis Patients in India. Biocon Ltd, Asia's premier biotechnology company, today introduced CANMAb (150 mg/ 440 mg), a biosimilar trastuzumab for the treatment of HER2-positive metastatic breast cancer in India. Latest Biocon Ltd (BIOCON:NSI) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. Buy Canmab 440mg Injection online at lowest price in India from Pillsbills.com. Buy Trastuzumab 440mg Injection online made by Biocon and its indian generic alternatives to treat cancer at lowest price in USA, UK, China, canada etc. Biocon Ltd, Asia's premier biotechnology company, today introduced CANMAb (150 mg/ 440 mg), a trastuzumab for the treatment of HER2-positive metastatic breast cancer in India. It is also available in two dosages in India Three months after the patent on Herceptin expired in India, ... marketed under the trade name Hertraz by Mylan and as CANMAb by Biocon. Latest Biocon Share Price ... BASALOG (Glargine), CANMAb (Trastuzumab ... Biosimilar Business Via Slump Sale As 'Going Concern' To Biocon Biologics India Packing: 440mg (1 Vial) ... What is Canmab ... Assistance Cell in India: For ONCOLOGY DRUG: price.Canmab (Trastuzumab) Contact Us Latest Biocon Ltd (BIOCON:NSI) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. Roche challenges Biocon, Mylan, DCGI over launch of biosimilar version of its breast cancer drug Herceptin Biocon defends price of biosimilars as it launches Herceptin copycat. Biocon offers affordable & convenient CANMAb to treat HER2-positive breast cancer in India ... which is already significantly lower than its price in developed markets. Biocon Ltd, Asia's premier biotechnology company, today introduced CANMAb (150 mg/ 440 mg), a trastuzumab for the treatment of HER2-positive metastatic breast cancer in India. Buy Canmab 440mg Injection - vial of 1 ml Injection at online at 1mg.com. A 440-mg vial has a maximum retail price Rs.57,500, while a 150mg Canmab. Biocons contribution to breast cancer by ... this drug in India, which is much sought after. Buy CANMAB 440MG INJECTION(BIOCON LIMITED) with a composition(formula) of Trastuzumab 440 MG at MRP of RS 57500.0. MUMBAI: Bangalore-based drugmaker Biocon on Saturday launched CANMAb, the biosimilar version of anti-cancer drug Herceptin, a move that analysts say would be a It is manufactured by Biocon/Mylan in India & is a considerably cheaper to Herclon. CANMAb, developed jointly by Biocon and Mylan under a global partnership, is being introduced for the benefit of patients in India. What is Canmab (Trastuzumab)? featured products of biocon: calpsor, canmab, cegava, cegava-tz, celrim, celrim-tz, ceracal, actiblok-am, actiblok-ipr, clasprin, clotide, cyclophil-me, cy Canmab, the brand name of the biosimilar trastuzumab, is a biological copy of Herceptin, the largest selling breast cancer drug in the world. Buy CANMAB 440MG INJECTION(BIOCON LIMITED) with a composition(formula) of Trastuzumab 440 MG at MRP of RS 57500.0. Buy Canmab 440mg Injection online at lowest price in India from Pillsbills.com.